Regeneron Pharmaceuticals, Inc.
REGN
$957.00
$19.392.07%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 6.55% | -5.53% | -11.63% | -25.95% | -25.22% |
| Total Other Revenue | 46.84% | 39.46% | 17.38% | 19.03% | 29.84% |
| Total Revenue | 7.76% | -4.47% | -10.94% | -25.07% | -24.26% |
| Cost of Revenue | 21.38% | 16.16% | 13.18% | -0.59% | -2.73% |
| Gross Profit | -2.25% | -17.43% | -24.74% | -37.28% | -34.84% |
| SG&A Expenses | 24.36% | 26.75% | 26.51% | 21.28% | 15.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 97.66% | 91.73% | -368.42% | -177.47% | -97.15% |
| Total Operating Expenses | 23.75% | 20.61% | 16.24% | 4.36% | 1.44% |
| Operating Income | -15.23% | -32.25% | -38.00% | -48.63% | -44.48% |
| Income Before Tax | -13.57% | -27.51% | -24.73% | -49.03% | -47.90% |
| Income Tax Expenses | -52.79% | -42.25% | -27.54% | -60.59% | -58.38% |
| Earnings from Continuing Operations | -8.87% | -25.68% | -24.40% | -47.28% | -46.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.87% | -25.68% | -24.40% | -47.28% | -46.28% |
| EBIT | -15.23% | -32.25% | -38.00% | -48.63% | -44.48% |
| EBITDA | -12.77% | -29.40% | -35.15% | -46.34% | -42.51% |
| EPS Basic | -8.55% | -25.75% | -24.71% | -47.95% | -47.01% |
| Normalized Basic EPS | -9.37% | -26.85% | -34.27% | -46.97% | -43.46% |
| EPS Diluted | -9.11% | -26.10% | -24.51% | -47.89% | -46.96% |
| Normalized Diluted EPS | -9.95% | -27.18% | -34.13% | -46.86% | -43.35% |
| Average Basic Shares Outstanding | -0.37% | -0.09% | 0.21% | 1.11% | 1.37% |
| Average Diluted Shares Outstanding | 0.26% | 0.49% | 0.11% | 0.84% | 1.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
